Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.

Author: , AlpersCharles E, BarrattJonathan, BielerStewart, ChaeDong-Wan, DivaUlysses A, FloegeJürgen, GesualdoLoreto, HeerspinkHiddo J L, InrigJula K, KohanDonald E, KomersRadko, KooiengaLaura Ann, LafayetteRichard, MaesBart, MałeckiRobert, MercerAlex, NoronhaIrene L, OhSe Won, PehChen Au, PerkovicVlado, PragaManuel, PreciadoPriscila, RadhakrishnanJai, RheaultMichelle N, RoteWilliam E, RovinBrad H, TangSydney C W, TesarVladimir, TrachtmanHoward, TrimarchiHernán, TumlinJames A, WongMuh Geot

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This report provides the final analysis of the PROTECT trial, showing that sparsentan, a dual endothelin angiotensin receptor antagonist, continued to significantly reduce proteinuria compared to irbesartan in patients with immunoglobulin A nephropathy over 110 weeks.
Paper Details　
Original Abstract of the Article :
Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(23)02302-4

データ提供：米国国立医学図書館（NLM）

Sparsentan vs. Irbesartan: Navigating the Desert of IgA Nephropathy

The world of nephrology is like a vast desert landscape, where the delicate balance of kidney function is constantly challenged. This study explores the effectiveness of two different medications, sparsentan and irbesartan, in treating IgA nephropathy, a complex kidney disorder. The researchers conducted a long-term study to compare the effects of these treatments on kidney function and overall outcomes. They were looking for a treatment that could effectively reduce proteinuria, a key indicator of kidney damage, and improve long-term kidney health.

A Promising Oasis: Sparsentan Shows Potential

The study found that sparsentan, a novel dual endothelin angiotensin receptor antagonist, was significantly more effective in reducing proteinuria compared to irbesartan, a traditional angiotensin II receptor blocker. The researchers observed this positive effect over a period of 110 weeks, highlighting the potential long-term benefits of sparsentan in managing IgA nephropathy. It’s like finding a sustainable source of water in a desert—sparsentan offers a potential long-term solution for managing kidney function in patients with this challenging condition.

Hope for Kidney Health

These findings offer hope for patients with IgA nephropathy. While more research is needed to fully understand the long-term effects of sparsentan and to determine its place in standard treatment protocols, this study suggests that a new, more effective treatment option might be on the horizon. Just as a desert landscape can be transformed by a nourishing rain, the landscape of IgA nephropathy management may be shifting, offering a new avenue for improved kidney health.

Dr.Camel's Conclusion

This study provides encouraging evidence that sparsentan could be a game-changer in the treatment of IgA nephropathy. It underscores the need for continued exploration of novel treatment options for this complex condition. Just as the desert landscape constantly evolves, so too does our understanding of kidney disease, and with each new discovery, we inch closer to a future where kidney health is more readily protected.

Date :
  1. Date Completed 2023-12-06
  2. Date Revised 2023-12-06
Further Info :

Pubmed ID

37931634

DOI: Digital Object Identifier

10.1016/S0140-6736(23)02302-4

Related Literature

Article Analysis
・Effects of sparsentan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.